Lv65
1860 积分 2024-05-22 加入
Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy
3天前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
2个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
3个月前
已完结
Non-small-cell lung cancer
5个月前
已完结
Top advances of the year: Ovarian cancer
5个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
5个月前
已完结
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study
6个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
6个月前
已完结
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
8个月前
已完结
Glioma
8个月前
已完结
皖公网安备34019202002308
